|
|
Volumn 5, Issue 3, 1999, Pages 256-257
|
|
The case for
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADENOSINE DEAMINASE;
BETA N ACETYLHEXOSAMINIDASE;
FUMARYLACETOACETASE;
GENE PRODUCT;
GLUCAN 1,4 ALPHA GLUCOSIDASE;
GLUCOSYLCERAMIDASE;
GLUCURONOSYLTRANSFERASE;
LAMININ;
ORNITHINE CARBAMOYLTRANSFERASE;
TRANSMEMBRANE CONDUCTANCE REGULATOR;
CYSTIC FIBROSIS;
EPIDERMOLYSIS BULLOSA;
GAUCHER DISEASE;
GENE TARGETING;
GENE THERAPY;
GLYCOGEN STORAGE DISEASE TYPE 2;
HEREDITARY SPINAL MUSCULAR ATROPHY;
HUNTER SYNDROME;
HURLER SYNDROME;
MUCOPOLYSACCHARIDOSIS TYPE 7;
NOTE;
PRENATAL DIAGNOSIS;
PRENATAL SCREENING;
PRIORITY JOURNAL;
TYROSINEMIA;
WERDNIG HOFFMANN DISEASE;
CLINICAL TRIAL;
FEMALE;
HUMAN;
LEGAL ASPECT;
METHODOLOGY;
RISK FACTOR;
UTERUS;
CLINICAL TRIALS;
FEMALE;
GENE THERAPY;
HUMANS;
RISK FACTORS;
UTERUS;
|
|
EID: 0033091484
PISSN: 10788956
EISSN: None
Source Type: Journal
DOI: 10.1038/6458 Document Type: Note |
|
Times cited : (44)
|
|
References (7)
|
